Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GrifolsGRFS -4.38%82 3-Year EBITDA Growth Rate is 11.10% as of Mar. 2026, which is 2% above its 10-year median of 10.85. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $8.90 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Grifols ranks better than 55.23% on this metric.
During the past 12 months, Grifols's average EBITDA Per Share Growth Rate was 12.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Grifols was 39.00% per year. The lowest was -8.30% per year. And the median was 10.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Grifols 3-Year EBITDA Growth Rate Related Terms
GRFS vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Grifols's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Grifols's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.10% mean?
Grifols (GRFS) has a 3-Year EBITDA Growth Rate of 11.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Grifols and its competitors. This is near median its historical median of 10.85. According to the industry distribution chart, Grifols ranks #364 out of 813 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Grifols' 3-Year EBITDA Growth Rate too high?
Grifols' current 3-Year EBITDA Growth Rate of 11.10% is near median its 10-year median of 10.85. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Grifols' value of 11.10% is 26.1% above this industry median. Based on the distribution chart, Grifols ranks #364 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #364 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Grifols in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Grifols' value of 11.10% is 26.1% above this benchmark. While the company's 10-year median is 10.85 vs. the industry median of 8.80, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current 3-Year EBITDA Growth Rate of 11.10% is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Grifols and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current 3-Year EBITDA Growth Rate is 11.10%, which is near median its own 10-year median of 10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.90, compared to a current price of $7.54 — trading 15.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.10%, which is near median its 10-year median of 10.85 and 26.1% above the Drug Manufacturers industry median of 8.80. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Grifols (GRFS), the current 3-Year EBITDA Growth Rate is 11.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.54 is trading 15.3% below its estimated GF Value™ of $8.90.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
3-Year EBITDA Growth Rate: 11.10% (near median its 10-year median of 10.85)
GF Value™: $8.90 vs. price of $7.54 (15.3% below fair value)
Industry Position: 26.1% above the Drug Manufacturers median (#364 of 813)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score
Get the complete analysis for GRFS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
